{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:51:22Z","timestamp":1789069882987,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T00:00:00Z","timestamp":1752969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100016003","name":"Istanbul \u00dcniversitesi-Cerrahpasa","doi-asserted-by":"crossref","award":["FBA-2024-37858"],"award-info":[{"award-number":["FBA-2024-37858"]}],"id":[{"id":"10.13039\/501100016003","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02927-7","type":"journal-article","created":{"date-parts":[[2025,7,20]],"date-time":"2025-07-20T21:57:06Z","timestamp":1753048626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A novel naphthoquinone compound triggers DNA damage-induced apoptosis on cholangiocarcinoma through upregulation of BAX"],"prefix":"10.1007","volume":"42","author":[{"given":"Gizem","family":"Bulut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Kayis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilan","family":"Gezer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeliha","family":"Gokmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelal","family":"Adiguzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engin","family":"Ulukaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,20]]},"reference":[{"issue":"7","key":"2927_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41571-023-00770-1","volume":"20","author":"SI Ilyas","year":"2023","unstructured":"Ilyas SI, Affo S, Goyal L, Lamarca A, Sapisochin G, Yang JD, Gores GJ. Cholangiocarcinoma\u2014novel biological insights and therapeutic strategies. Nat Rev Clin Oncol. 2023;20(7):470\u201386.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2927_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.urolonc.2022.06.019","volume":"41","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, Shan ZJ, Yang JF, Len JJ, Yu YH, Yang ML. Nephrometric scoring system: recent advances and outlooks. Urol Oncol Semin Original Investig. 2023;41(1):15\u201326.","journal-title":"Urol Oncol Semin Original Investig"},{"issue":"12","key":"2927_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1007\/s12094-015-1436-2","volume":"17","author":"M Benavides","year":"2015","unstructured":"Benavides M, Ant\u00f3n A, Gallego J, G\u00f3mez MA, Jim\u00e9nez-Gordo A, La Casta A, et al. Biliary tract cancers: SEOM clinical guidelines. Clin Transl Oncol. 2015;17(12):982\u20137. https:\/\/doi.org\/10.1007\/s12094-015-1436-2.","journal-title":"Clin Transl Oncol"},{"issue":"11","key":"2927_CR4","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.21037\/tcr-23-1278","volume":"12","author":"JQ Yang","year":"2023","unstructured":"Yang JQ, Wang XG, Wu B. Incidence trend and prognosis of intrahepatic cholangiocarcinoma: a study based on the SEER database. Transl Cancer Res. 2023;12(11):3007\u201315. https:\/\/doi.org\/10.21037\/tcr-23-1278.","journal-title":"Transl Cancer Res"},{"issue":"9","key":"2927_CR5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Ba\u00f1ales","year":"2020","unstructured":"Ba\u00f1ales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2927_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2023.107064","author":"M Qurashi","year":"2023","unstructured":"Qurashi M, Vithayathil M, Khan SA. Epidemiology of cholangiocarcinoma. Eur J Surg Oncol. 2023. https:\/\/doi.org\/10.1016\/j.ejso.2023.107064.","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"2927_CR7","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(05)67530-7","volume":"73","author":"SA Khan","year":"2021","unstructured":"Khan SA, Thomas HC, Davidson BR. Cholangiocarcinoma: current treatment algorithms. Hepatology. 2021;73(2):797\u2013810. https:\/\/doi.org\/10.1016\/s0140-6736(05)67530-7.","journal-title":"Hepatology"},{"key":"2927_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","volume":"3","author":"A Pellino","year":"2018","unstructured":"Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, et al. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol. 2018;3:40. https:\/\/doi.org\/10.21037\/tgh.2018.07.02.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"5","key":"2927_CR9","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","volume":"76","author":"L Izquierdo-Sanchez","year":"2022","unstructured":"Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Kl\u00fcmpen HJ, et al. Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022;76(5):1109\u201321. https:\/\/doi.org\/10.1016\/j.jhep.2021.12.010.","journal-title":"J Hepatol"},{"issue":"6","key":"2927_CR10","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","volume":"149","author":"MN Mavros","year":"2014","unstructured":"Mavros MN, Economopoulos KP, Alexiou VG, Pawlik TM. Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis. JAMA Surg. 2014;149(6):565\u201374. https:\/\/doi.org\/10.1001\/jamasurg.2013.5137.","journal-title":"JAMA Surg"},{"issue":"3","key":"2927_CR11","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.31803","volume":"74","author":"Y Wada","year":"2021","unstructured":"Wada Y, Shimada M, Yamamura K, Toshima T, Banwait JK, Morine Y, Goel A. A transcriptomic signature for risk-stratification and recurrence prediction in intrahepatic cholangiocarcinoma. Hepatology. 2021;74(3):1371\u201383.","journal-title":"Hepatology"},{"key":"2927_CR12","doi-asserted-by":"publisher","first-page":"107612","DOI":"10.1016\/j.compbiomed.2023.107612","volume":"167","author":"B Chen","year":"2023","unstructured":"Chen B, Mao Y, Li J, Zhao Z, Chen Q, Yu Y, Xie X. Predicting very early recurrence in intrahepatic cholangiocarcinoma after curative hepatectomy using machine learning radiomics based on CECT: a multi-institutional study. Comput Biol Med. 2023;167:107612.","journal-title":"Comput Biol Med"},{"issue":"2","key":"2927_CR13","first-page":"198","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73(2):198\u2013222.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2927_CR14","doi-asserted-by":"publisher","first-page":"801","DOI":"10.3390\/cancers16040801","volume":"16","author":"D Khosla","year":"2024","unstructured":"Khosla D, Misra S, Chu PL, Guan P, Nada R, Gupta R, et al. Cholangiocarcinoma: recent advances in molecular pathobiology and therapeutic approaches. Cancers. 2024;16(4):801. https:\/\/doi.org\/10.3390\/cancers16040801.","journal-title":"Cancers"},{"key":"2927_CR15","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ejmech.2014.08.061","volume":"97","author":"A Gaspar","year":"2015","unstructured":"Gaspar A, Matos MJ. Naphthoquinones: an overview of their medicinal chemistry. Eur J Med Chem. 2015;97:624\u201361. https:\/\/doi.org\/10.1016\/j.ejmech.2014.08.061.","journal-title":"Eur J Med Chem"},{"issue":"4","key":"2927_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3390\/ph16040496","volume":"16","author":"G Navarro-Tovar","year":"2023","unstructured":"Navarro-Tovar G, Vega-Rodr\u00edguez S, Leyva E, Loredo-Carrillo S, de Loera D, L\u00f3pez-L\u00f3pez LI. The relevance and insights on 1,4-naphthoquinones as antimicrobial and antitumoral molecules: a systematic review. Pharmaceutics. 2023;16(4):496. https:\/\/doi.org\/10.3390\/ph16040496.","journal-title":"Pharmaceutics"},{"issue":"4","key":"2927_CR17","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1080\/1120009x.2019.1610832","volume":"31","author":"JR Wang","year":"2019","unstructured":"Wang JR, Shen GN, Luo YH, Piao XJ, Zhang Y, Wang H, et al. 2-(4-Methoxyphenylthio)-5,8-dimethoxy-1,4-naphthoquinone induces apoptosis via ROS-mediated MAPK and STAT3 signaling pathway in human gastric cancer cells. J Chemother. 2019;31(4):214\u201326. https:\/\/doi.org\/10.1080\/1120009x.2019.1610832.","journal-title":"J Chemother"},{"key":"2927_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biocel.2018.01.004","volume":"96","author":"C Liu","year":"2018","unstructured":"Liu C, Shen GN, Luo YH, Piao XJ, Jiang XY, Meng LQ, et al. Novel 1,4-naphthoquinone derivatives induce apoptosis via ROS-mediated p38\/MAPK, Akt and STAT3 signaling in human hepatoma Hep3B cells. Int J Biochem Cell Biol. 2018;96:9\u201319. https:\/\/doi.org\/10.1016\/j.biocel.2018.01.004.","journal-title":"Int J Biochem Cell Biol"},{"issue":"8","key":"2927_CR19","doi-asserted-by":"publisher","first-page":"3698","DOI":"10.5958\/0974-360X.2018.00679.0","volume":"11","author":"BR Jali","year":"2018","unstructured":"Jali BR, Behura R, Barik SR, Parveen S, Mohanty SP, Das RA. A brief review: biological implications of naphthoquinone derivatives. Res J Pharm Technol. 2018;11(8):3698\u2013702. https:\/\/doi.org\/10.5958\/0974-360X.2018.00679.0.","journal-title":"Res J Pharm Technol"},{"issue":"4","key":"2927_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3906\/biy-1901-19","volume":"43","author":"ZD Karaka\u015f","year":"2019","unstructured":"Karaka\u015f ZD, Akar RO, Gokmen Z, Deniz NG, Ulukaya E. A novel 1,4-naphthoquinone-derived compound induces apoptotic cell death in breast cancer cells. Turk J Biol. 2019;43(4):256\u201363. https:\/\/doi.org\/10.3906\/biy-1901-19.","journal-title":"Turk J Biol"},{"issue":"8","key":"2927_CR21","doi-asserted-by":"publisher","first-page":"e202301955","DOI":"10.1002\/slct.202301955","volume":"43","author":"K Adacan","year":"2023","unstructured":"Adacan K, Gokmen Z, Akar RO, Ozy\u0131ld\u0131z Z, Din\u00e7er H, Karaka\u015f D, Ulukaya E. Synthesis, characterization and apoptosis capabilities of a novel naphthoquinone-derived compound in triple-negative breast cancer. ChemistrySelect. 2023;43(8):e202301955. https:\/\/doi.org\/10.1002\/slct.202301955.","journal-title":"ChemistrySelect"},{"issue":"2","key":"2927_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1177\/09731296231158221","volume":"19","author":"B Buranrat","year":"2023","unstructured":"Buranrat B, Utsintong M. Plumbagin suppresses growth, induces apoptosis, and inhibits migration in cholangiocarcinoma via reactive oxygen species generation and mitochondrial function. Pharmacogn Mag. 2023;19(2):325\u201335. https:\/\/doi.org\/10.1177\/09731296231158221.","journal-title":"Pharmacogn Mag"},{"issue":"12","key":"2927_CR23","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.3155\/APJCP.2018.19.12.3605","volume":"19","author":"P Boueroy","year":"2018","unstructured":"Boueroy P, Saensa-Ard S, Siripong P, Kanthawong S, Hahnvajanawong C. Rhinacanthin-C extracted from Rhinacanthus nasutus (L.) inhibits cholangiocarcinoma cell migration and invasion by decreasing MMP-2, uPA, FAK and MAPK pathways. Asian Pac J Cancer Prevention (APJCP). 2018;19(12):3605\u201313. https:\/\/doi.org\/10.3155\/APJCP.2018.19.12.3605.","journal-title":"Asian Pac J Cancer Prevention (APJCP)"},{"key":"2927_CR24","doi-asserted-by":"publisher","first-page":"156022","DOI":"10.1016\/j.phymed.2024.156022","volume":"135","author":"B Chen","year":"2024","unstructured":"Chen B, Chen Q, Lu M, Zou E, Lin G, Yao J, Wu L. Hypocrellin A against intrahepatic cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways. Phytomedicine. 2024;135:156022.","journal-title":"Phytomedicine"},{"issue":"5","key":"2927_CR25","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.3892\/or.2014.3059","volume":"31","author":"D Xu","year":"2014","unstructured":"Xu D, Ma Y, Zhao B, Li S, Zhang YU, Pan S, Jiang H. Thymoquinone induces G2\/M arrest, inactivates PI3K\/Akt and nuclear factor-\u03baB pathways in human cholangiocarcinomas both in vitro and in vivo. Oncol Rep. 2014;31(5):2063\u201370.","journal-title":"Oncol Rep"},{"issue":"23","key":"2927_CR26","doi-asserted-by":"publisher","first-page":"14669","DOI":"10.3390\/ijms232314669","volume":"23","author":"RJ Abdualmjid","year":"2022","unstructured":"Abdualmjid RJ, Sergi CM. Mitochondrial dysfunction and induction of apoptosis in hepatocellular carcinoma and cholangiocarcinoma cell lines by thymoquinone. Int J Mol Sci. 2022;23(23):14669. https:\/\/doi.org\/10.3390\/ijms232314669.","journal-title":"Int J Mol Sci"},{"key":"2927_CR27","doi-asserted-by":"publisher","first-page":"963689720979162","DOI":"10.1177\/0963689720979162","volume":"30","author":"C Liu","year":"2021","unstructured":"Liu C, Xuan LQ, Li K, Feng Z, Lv C, Li XJ, Ji XD, Wan R, Shen J. Shikonin inhibits cholangiocarcinoma cell line QBC939 by regulating apoptosis, proliferation, and invasion. Cell Transplant. 2021;30:963689720979162. https:\/\/doi.org\/10.1177\/0963689720979162.","journal-title":"Cell Transplant"},{"issue":"21","key":"2927_CR28","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1080\/00397911.2019.1655057","volume":"49","author":"Z Gokmen","year":"2019","unstructured":"Gokmen Z, Onan ME, Deniz NG, Karakas D, Ulukaya ES. Synthesis and investigation of cytotoxicity of new N-and S, S-substituted-1,4-naphthoquinone (1,4-NQ) derivatives on selected cancer lines. Synth Commun. 2019;49(21):3008\u201316. https:\/\/doi.org\/10.1080\/00397911.2019.1655057.","journal-title":"Synth Commun"},{"issue":"9","key":"2927_CR29","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1080\/10426507.2020.1755973","volume":"195","author":"Z Gokmen","year":"2020","unstructured":"Gokmen Z, Alahmad H. Novel amino- and thio(substituted)-1,4-naphthoquinone (NQ) compounds: synthesis and characterization. Phosphorus Sulfur Silicon Relat Elem. 2020;195(9):718\u201325. https:\/\/doi.org\/10.1080\/10426507.2020.1755973.","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"issue":"12","key":"2927_CR30","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1248\/cpb.c15-00607","volume":"63","author":"NG Deniz","year":"2015","unstructured":"Deniz NG, Ibis C, Gokmen Z, Stasevych M, Novikov V, Komarovska-Porokhnyavets O, Ozyurek M, Guclu K, Karakas D, Ulukaya E. Design, synthesis, biological evaluation, and antioxidant and cytotoxic activity of heteroatom-substituted 1,4-naphtho- and benzoquinones. Chem Pharm Bull. 2015;63(12):1029\u201339. https:\/\/doi.org\/10.1248\/cpb.c15-00607.","journal-title":"Chem Pharm Bull"},{"key":"2927_CR31","unstructured":"Pfizer. (n.d.). Doxorubicin hydrochloride: clinical pharmacology. Pfizer Medical Information. https:\/\/www.pfizermedicalinformation.com\/doxorubicin\/clinical-pharmacology."},{"issue":"1","key":"2927_CR32","doi-asserted-by":"publisher","first-page":"18562","DOI":"10.1038\/s41598-020-75662-w","volume":"10","author":"C Siebel","year":"2020","unstructured":"Siebel C, Lanvers-Kaminsky C, W\u00fcrthwein G, Hempel G, Boos J. Bioanalysis of doxorubicin aglycone metabolites in human plasma samples\u2013implications for doxorubicin drug monitoring. Sci Rep. 2020;10(1):18562.","journal-title":"Sci Rep"},{"issue":"11","key":"2927_CR33","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/jnci\/83.11.757","volume":"83","author":"A Monks","year":"1991","unstructured":"Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst (JNCI). 1991;83(11):757\u201366. https:\/\/doi.org\/10.1093\/jnci\/83.11.757.","journal-title":"J Natl Cancer Inst (JNCI)"},{"issue":"11","key":"2927_CR34","doi-asserted-by":"publisher","first-page":"e2000607","DOI":"10.1002\/cbdv.202000607","volume":"17","author":"M Erkisa","year":"2020","unstructured":"Erkisa M, Ari F, Ulku I, Khodadust R, Yar Y, Yagci Acar H, Ulukaya E. Etoposide loaded SPION-PNIPAM nanoparticles improve the in vitro therapeutic outcome on metastatic prostate cancer cells via enhanced apoptosis. Chem Biodivers. 2020;17(11):e2000607. https:\/\/doi.org\/10.1002\/cbdv.202000607.","journal-title":"Chem Biodivers"},{"issue":"1","key":"2927_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000077285","volume":"50","author":"E Ulukaya","year":"2004","unstructured":"Ulukaya E, Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT-tumor chemosensitivity assay. Chemotherapy. 2004;50(1):43\u201350. https:\/\/doi.org\/10.1159\/000077285.","journal-title":"Chemotherapy"},{"issue":"4","key":"2927_CR36","doi-asserted-by":"publisher","first-page":"842","DOI":"10.20892\/j.issn.2095-3941.2020.0005","volume":"17","author":"YJ Chern","year":"2020","unstructured":"Chern YJ, Tai IT. Adaptive response of resistant cancer cells to chemotherapy. Cancer Biol Med. 2020;17(4):842\u201363. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0005.","journal-title":"Cancer Biol Med"},{"key":"2927_CR37","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s11626-019-00333-8","volume":"55","author":"C O\u2019Doherty","year":"2019","unstructured":"O\u2019Doherty C, Keenan J, Horgan K, Murphy R, O\u2019Sullivan F, Clynes M. Copper-induced non-monotonic dose response in Caco-2 cells. In Vitro Cell Dev Biol Anim. 2019;55:221\u20135. https:\/\/doi.org\/10.1007\/s11626-019-00333-8.","journal-title":"In Vitro Cell Dev Biol Anim"},{"issue":"6","key":"2927_CR38","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/cbf.1774","volume":"29","author":"E Ulukaya","year":"2011","unstructured":"Ulukaya E, Acilan C, Yilmaz Y. Apoptosis: why and how does it occur in biology? Cell Biochem Funct. 2011;29(6):468\u201380. https:\/\/doi.org\/10.1002\/cbf.1774.","journal-title":"Cell Biochem Funct"},{"issue":"22","key":"2927_CR39","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1016\/j.febslet.2010.10.046","volume":"584","author":"MT Silva","year":"2010","unstructured":"Silva MT. Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett. 2010;584(22):4491\u20139. https:\/\/doi.org\/10.1016\/j.febslet.2010.10.046.","journal-title":"FEBS Lett"},{"issue":"4","key":"2927_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1002\/ijc.1639","volume":"97","author":"K Caca","year":"2002","unstructured":"Caca K, Feisthammel J, Klee K, Tannapfel A, Witzigmann H, Wittekind C, et al. Inactivation of the INK4a\/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines. Int J Cancer. 2002;97(4):481\u20138. https:\/\/doi.org\/10.1002\/ijc.1639.","journal-title":"Int J Cancer"},{"issue":"5","key":"2927_CR41","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/biomedicines11051310","volume":"11","author":"CC Chen","year":"2023","unstructured":"Chen CC, Liao RY, Yeh FY, Lin YR, Wu TY, Pastor AE, et al. A simple and affordable method to create nonsense mutation clones of p53 for studying the premature termination codon readthrough activity of PTC124. Biomedicines. 2023;11(5):1310. https:\/\/doi.org\/10.3390\/biomedicines11051310.","journal-title":"Biomedicines"},{"issue":"9","key":"2927_CR42","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.chembiol.2015.07.016","volume":"22","author":"M Hiraki","year":"2015","unstructured":"Hiraki M, Hwang SY, Cao S, Ramadhar TR, Byun S, Yoon KW, Lee SW. Small-molecule reactivation of mutant p53 to wild-type-like p53 through the p53-Hsp40 regulatory axis. Chem Biol. 2015;22(9):1206\u201316.","journal-title":"Chem Biol"},{"issue":"2","key":"2927_CR43","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/ijc.2910520217","volume":"52","author":"Y Shimizu","year":"1992","unstructured":"Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, Whiteside TL. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer. 1992;52(2):252\u201360.","journal-title":"Int J Cancer"},{"issue":"6","key":"2927_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF02623562","volume":"25","author":"M Miyagiwa","year":"1989","unstructured":"Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19\/9 in serum-free medium. In Vitro Cell Dev Biol. 1989;25(6):503\u201310. https:\/\/doi.org\/10.1007\/BF02623562.","journal-title":"In Vitro Cell Dev Biol"},{"issue":"7","key":"2927_CR45","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/onc.2009.376","volume":"29","author":"DP Liu","year":"2010","unstructured":"Liu DP, Song H, Xu Y. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene. 2010;29(7):949\u201356. https:\/\/doi.org\/10.1038\/onc.2009.376.","journal-title":"Oncogene"},{"issue":"23","key":"2927_CR46","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1038\/onc.2012.299","volume":"32","author":"X Lu","year":"2013","unstructured":"Lu X, Liu DP, Xu Y. The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene. 2013;32(23):2900\u20136. https:\/\/doi.org\/10.1038\/onc.2012.299.","journal-title":"Oncogene"},{"issue":"3","key":"2927_CR47","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304\u201317. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.021.","journal-title":"Cancer Cell"},{"issue":"13","key":"2927_CR48","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1038\/sj.onc.1207396","volume":"23","author":"A Willis","year":"2004","unstructured":"Willis A, Jung EJ, Wakefield T, Chen X. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene. 2004;23(13):2330\u20138. https:\/\/doi.org\/10.1038\/sj.onc.1207396.","journal-title":"Oncogene"},{"issue":"3","key":"2927_CR49","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","volume":"77","author":"C Raggi","year":"2022","unstructured":"Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77(3):849\u201364. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.038.","journal-title":"J Hepatol"},{"issue":"10","key":"2927_CR50","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1111\/liv.15366","volume":"42","author":"M Tanaka","year":"2022","unstructured":"Tanaka M, Kunita A, Yamagishi M, Katoh H, Ishikawa S, Yamamoto H, Ushiku T. KRAS mutation in intrahepatic cholangiocarcinoma: linkage with metastasis-free survival and reduced E-cadherin expression. Liver Int. 2022;42(10):2329\u201340.","journal-title":"Liver Int"},{"key":"2927_CR51","doi-asserted-by":"publisher","first-page":"116256","DOI":"10.1016\/j.taap.2022.116256","volume":"456","author":"EL Silva","year":"2022","unstructured":"Silva EL, Mesquita FP, Ramos INF, Gomes CBSMR, Moreira CDS, Ferreira VF, et al. Antitumoral effect of novel synthetic 8-hydroxy-2-((4-nitrophenyl)thio)naphthalene-1,4-dione (CNN16) via ROS-mediated DNA damage, apoptosis, and anti-migratory effect in colon cancer cell line. Toxicol Appl Pharmacol. 2022;456:116256. https:\/\/doi.org\/10.1016\/j.taap.2022.116256.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2927_CR52","doi-asserted-by":"publisher","first-page":"117671","DOI":"10.1016\/j.bmc.2024.117671","volume":"102","author":"AS de Souza","year":"2024","unstructured":"de Souza AS, Dias DS, Ribeiro RCB, Costa DCS, de Moraes MG, Pinho DR, et al. Novel naphthoquinone-1H-1,2,3-triazole hybrids: Design, synthesis and evaluation as inductors of ROS-mediated apoptosis in the MCF-7 cells. Bioorg Med Chem. 2024;102:117671. https:\/\/doi.org\/10.1016\/j.bmc.2024.117671.","journal-title":"Bioorg Med Chem"},{"issue":"8","key":"2927_CR53","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.bmc.2019.03.002","volume":"27","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Luo YH, Piao XJ, Shen GN, Wang JR, Feng YC, et al. The design of 1,4-naphthoquinone derivatives and mechanisms underlying apoptosis induction through ROS-dependent MAPK\/Akt\/STAT3 pathways in human lung cancer cells. Bioorg Med Chem. 2019;27(8):1577\u201387. https:\/\/doi.org\/10.1016\/j.bmc.2019.03.002.","journal-title":"Bioorg Med Chem"},{"key":"2927_CR54","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12935-019-0925-8","volume":"19","author":"CE Pereyra","year":"2019","unstructured":"Pereyra CE, Dantas RF, Ferreira SB, Gomes LP, Silva-Jr FP. The diverse mechanisms and anticancer potential of naphthoquinones. Cancer Cell Int. 2019;19:207. https:\/\/doi.org\/10.1186\/s12935-019-0925-8.","journal-title":"Cancer Cell Int"},{"issue":"10","key":"2927_CR55","doi-asserted-by":"publisher","first-page":"4725","DOI":"10.21873\/anticanres.15287","volume":"41","author":"R Gharbaran","year":"2021","unstructured":"Gharbaran R, Shi C, Onwumere O, Redenti S. Plumbagin induces cytotoxicity via loss of mitochondrial membrane potential and caspase activation in metastatic retinoblastoma. Anticancer Res. 2021;41(10):4725\u201332. https:\/\/doi.org\/10.21873\/anticanres.15287.","journal-title":"Anticancer Res"},{"issue":"3","key":"2927_CR56","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.21873\/anticanres.16912","volume":"44","author":"PH Chen","year":"2024","unstructured":"Chen PH, Lu HK, Renn TY, Chang TM, Lee CJ, Tsao YT, Chuang P, Liu JF. Plumbagin induces reactive oxygen species and endoplasmic reticulum stress-related cell apoptosis in human oral squamous cell carcinoma. Anticancer Res. 2024;44(3):1173\u201382. https:\/\/doi.org\/10.21873\/anticanres.16912.","journal-title":"Anticancer Res"},{"issue":"26","key":"2927_CR57","doi-asserted-by":"publisher","first-page":"20309","DOI":"10.1039\/C4RA13547D","volume":"5","author":"KW Wellington","year":"2015","unstructured":"Wellington KW. Understanding cancer and the anticancer activities of naphthoquinones\u2014a review. RSC Adv. 2015;5(26):20309\u201338. https:\/\/doi.org\/10.1039\/C4RA13547D.","journal-title":"RSC Adv"},{"issue":"7","key":"2927_CR58","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440\u20136. https:\/\/doi.org\/10.1097\/FPC.0b013e32833ffb56.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"2927_CR59","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1038\/s41598-018-22484-6","volume":"8","author":"J Liu","year":"2018","unstructured":"Liu J, Jiang G, Mao P, Zhang J, Zhang L, Liu L, et al. Down-regulation of gadd45a enhances chemosensitivity in melanoma. Sci Rep. 2018;8(1):4111. https:\/\/doi.org\/10.1038\/s41598-018-22484-6.","journal-title":"Sci Rep"},{"issue":"4","key":"2927_CR60","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3892\/or.2013.2613","volume":"30","author":"H Jung","year":"2013","unstructured":"Jung H, Kim H, Kim Y, Weon J, Seo Y. A novel chemopreventive mechanism of selenomethionine: enhancement of ape1 enzyme activity via a gadd45a, pcna and ape1 protein complex that regulates p53-mediated base excision repair. Oncol Rep. 2013;30(4):1581\u20136. https:\/\/doi.org\/10.3892\/or.2013.2613.","journal-title":"Oncol Rep"},{"issue":"5","key":"2927_CR61","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/cancers12051129","volume":"12","author":"AA Artykov","year":"2020","unstructured":"Artykov AA, Belov DA, Shipunova VO, Trushina DB, Deyev SM, Dolgikh DA, et al. Chemotherapeutic agents sensitize resistant cancer cells to the DR5-specific variant DR5-B more efficiently than to TRAIL by modulating the surface expression of death and decoy receptors. Cancers. 2020;12(5):1129. https:\/\/doi.org\/10.3390\/cancers12051129.","journal-title":"Cancers"},{"issue":"5","key":"2927_CR62","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.pharep.2016.04.010","volume":"68","author":"PY Yang","year":"2016","unstructured":"Yang PY, Hu DN, Kao YH, Lin IC, Chou CY, Wu YC. Norcantharidin induces apoptosis in human prostate cancer cells through both intrinsic and extrinsic pathways. Pharmacol Rep. 2016;68(5):874\u201380. https:\/\/doi.org\/10.1016\/j.pharep.2016.04.010.","journal-title":"Pharmacol Rep"},{"key":"2927_CR63","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.2147\/ott.s73731","volume":"8","author":"Y Dong","year":"2015","unstructured":"Dong Y, Yang G, Deng H, Chen W, An G. Gefitinib upregulates death receptor 5 expression to mediate rmhtrail-induced apoptosis in gefitinib-sensitive nsclc cell line. Oncotargets Ther. 2015;8:1603\u201310. https:\/\/doi.org\/10.2147\/ott.s73731.","journal-title":"Oncotargets Ther"},{"issue":"8","key":"2927_CR64","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/CAD.0b013e328347181a","volume":"22","author":"D Eum","year":"2011","unstructured":"Eum D, Byun J, Yoon C, Seo W, Park K, Lee J, et al. Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction. Anticancer Drugs. 2011;22(8):763\u201373. https:\/\/doi.org\/10.1097\/CAD.0b013e328347181a.","journal-title":"Anticancer Drugs"},{"issue":"6","key":"2927_CR65","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.3892\/or.2019.7355","volume":"42","author":"H Zheng","year":"2019","unstructured":"Zheng H, Zhang Y, Zhan Y, Liu S, Lu J, Wen Q, et al. Expression of DR5 and c flip proteins as novel prognostic biomarkers for non-small cell lung cancer patients treated with surgical resection and chemotherapy. Oncol Rep. 2019;42(6):2363\u201370. https:\/\/doi.org\/10.3892\/or.2019.7355.","journal-title":"Oncol Rep"},{"issue":"4","key":"2927_CR66","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1007\/s43440-020-00073-7","volume":"72","author":"S Surapally","year":"2020","unstructured":"Surapally S, Jayaprakasam M, Verma RS. Curcumin augments therapeutic efficacy of TRAIL-based immunotoxins in leukemia. Pharmacol Rep. 2020;72(4):1032\u201346. https:\/\/doi.org\/10.1007\/s43440-020-00073-7.","journal-title":"Pharmacol Rep"},{"issue":"1","key":"2927_CR67","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41419-025-07403-8","volume":"16","author":"F Zappa","year":"2025","unstructured":"Zappa F, Muniozguren NL, Conrad JE, Acosta-Alvear D. The integrated stress response engages a cell-autonomous, ligand-independent, DR5-driven apoptosis switch. Cell Death Dis. 2025;16(1):101.","journal-title":"Cell Death Dis"},{"issue":"8","key":"2927_CR68","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41418-018-0155-y","volume":"25","author":"M Lam","year":"2018","unstructured":"Lam M, Lawrence DA, Ashkenazi A, Walter P. Confirming a critical role for death receptor 5 and caspase-8 in apoptosis induction by endoplasmic reticulum stress. Cell Death Differ. 2018;25(8):1530\u20131.","journal-title":"Cell Death Differ"},{"issue":"2","key":"2927_CR69","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3390\/life12020256","volume":"12","author":"R Roufayel","year":"2022","unstructured":"Roufayel R, Younes K, Al-Sabi A, Murshid N. BH3-only proteins Noxa and Puma are key regulators of induced apoptosis. Life (Basel, Switzerland). 2022;12(2):256. https:\/\/doi.org\/10.3390\/life12020256.","journal-title":"Life (Basel, Switzerland)"},{"issue":"4","key":"2927_CR70","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1158\/1541-7786.MCR-14-0476","volume":"13","author":"K Okamoto","year":"2015","unstructured":"Okamoto K, Zaanan A, Kawakami H, Huang S, Sinicrope FA. Reversal of mutant KRAS-mediated apoptosis resistance by concurrent Noxa\/Bik induction and Bcl-2\/Bcl-xL antagonism in colon cancer cells. Mol Cancer Res. 2015;13(4):659\u201369.","journal-title":"Mol Cancer Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02927-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02927-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02927-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T16:01:21Z","timestamp":1757260881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02927-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,20]]},"references-count":70,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2927"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02927-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6395590\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,20]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"354"}}